Direct renin inhibition with aliskiren normalizes blood pressure in cyp1a1-Ren2 transgenic rats with inducible angiotensin II-dependent malignant hypertension

American Journal of the Medical Sciences

Volumn 341, Issue 5, 2011, Pages 383-387

  Howard, Catherine G ^a   Mullins, John J ^b   Mitchell, Kenneth D ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Kidney; Malignant hypertension; Renal hemodynamics; Renin inhibitor; Renin angiotensin system

Indexed keywords

3 INDOLEMETHANOL; ALISKIREN; ANGIOTENSIN II; CYTOCHROME P450 1A1; PENTOBARBITAL; RENIN; RENIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; MALE; MALIGNANT HYPERTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT;

EID: 79955524321     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31820fa8da     Document Type: Article

References (13)

1. Kantachuvesiri S, Fleming S, Peters J, et al. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 2001;276:36727-33.
2. Campbell SJ, Carlotti F, Hall PA, et al. Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 1996;109:2619-25. (Pubitemid 26388347)
3. Loub WD, Wattenberg LW, Davis DW. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst 1975;54:985-8.
4. Vanourková Z, Kramer HJ, Erbanová M, et al. Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension. Vascul Pharmacol 2009;50:194-9.
5. Graciano ML, Mouton CR, Patterson ME, et al. Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 2007;292:F1858-66. (Pubitemid 47105375)
6. Mitchell KD, Bagatell SJ, Miller CS, et al. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal Ang II levels of graded severity in Cyp1a1-Ren2 transgenic rats. J Renin Angiotensin Aldosterone Syst 2006;7:74-86. (Pubitemid 44383501)
7. Mitchell KD, Mullins JJ. Enhanced tubuloglomerular feedback in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol 2005;289:F1210-6. (Pubitemid 41681356)
8. Feldman DL. New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertens Res 2010; 33:279-87.
9. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76. (Pubitemid 41376839)
10. Nussberger J, Gradman AH, Schmieder RE, et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007;61:1461-8. (Pubitemid 47228610)
11. Whaley-Connell A, Habibi J, Cooper SA, et al. Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab 2008;295:E103-9.
12. Rakusan D, Kujal P, Kramer HJ, et al. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol 2010;299:F758-66.
13. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;52:130-6.